Northstar was founded in 1999 as Vertis Neuroscience headquartered in Seattle, WA, and the original goal was to develop electrical stimulation for chronic back pain. In 2003, under its new name, Northstar Neuroscience, then developed the Renova cortical stimulation system to deliver targeted electrical stimulation to the brain cortex as a treatment for stroke-related upper extremity.
Intrapace was founded in Mountain View, CA by Mir Imran in 2001 to develop an implantable system for the treatment of obesity. Once implanted and activated, the Abiliti system is designed to detect when a person consumes food or drink. When food or drink is detected, the system delivers a series of low-energy electrical impulses to the
Transneuronix, Inc. was founded in 1995 and was based in Mount Arlington, New Jersey. It was acquired by Medtronic in 2005. Before its acqusition by Medtronic, Transneuronix developed the Transcend, an implantable gastric stimulator device for the treatment of obesity by electrical stimulation of the stomach. Later, Medtronic developed the Transcend II IPG.
EnteroMedics Inc. was founded in St. Paul, MN in 2002 to develop a platform for vagus-nerve stimulation, primarily for obesity management. In March 2011 EnteroMedics received the CE Mark for its second-generation system – the Maestro RC. The EnteroMedics Maestro RC device delivers VBLOC® vagal blocking therapy to through laparoscopically implanted leads to intermittently block the vagus nerves using
Transoma was the name that Data Sciences International of St Paul, MN adopted in 2003 when it re-fucused its animal telemetry implant business to develop an implantable wireless system to capture electrocardiogram data for diagnosing human cardiac arrhythmias, as well as to monitor the electrical activity of the heart and transmit data from the patient’s home
In June 2011, Israeli neuromodulation systems developer BioControl Medical spun-off CerebralRx to market its FitNeS vagus nerve stimulation system for the treatment of refractory epilepsy. The FitNes system employs platform technology developed for the CardioFit® system for treating congestive heart failure (HF). CerebralRx spun out of BioControl Medical to expand the use of this technology outside of cardiology for the
Enopace Biomedical Ltd. was founded in 2008 by Yossi Gross in Caesarea, Israel. Very scant details are available besides that it is developing a neuromodulation system to treat patients with congestive heart failure. According to the company, its technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload. From Enopace’s patent
CVRx was founded in Minneapolis, MN in 2001 by Dr. Robert Kieval to develop an implantable system for the treatment of hypertension. CVRx’s implantable pulse generators deliver stimulation to the baroeceptors in the carotid arteries to induce a baroreflex that causes a drop in blood pressure in patients with refractory hypertension.
Second Sight Medical Products, Inc., located in Los Angeles, CA, was founded in 1998 by Alfred Mann to develop a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations, such as Retinitis Pigmentosa. Second Sight’s Argus II Retinal Prosthesis System is intended to provide electrical stimulation of the retina to induce visual
St. Louis, MO startup EndoStim is developing an implantable stimulator to treat gastro-esophageal reflux disease (GERD) by delivering stimulation to the lower esophageal sphincter. The IPG is connected to an EndoStim implantable bipolar lead with electrodes that are stitched and secured into the lower esophageal sphincter muscle during laparoscopy.
Sicel Technologies, Inc. was founded in 1999 and was based in Morrisville, NC. It ceased operations in 2010 after it declared bankruptcy. Sicel developed an implantable dosimeter that was 2 mm in diameter and 18 mm long, and was injected into the tumor to send back readings to an external receiver via RFID.
Alfred E. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel), as well as, Research Professor, University of Southern California, and Adjunct Professor, Dept. of Bioengineering, University of
Dr. Fischell received his BSME degree from Duke University and MS and Sc.D. degrees from the University of Maryland. Dr. Fischell was employed at the Johns Hopkins University where he was the Chief Engineer of the Space Department and worked on more than 50 spacecraft. His interests at Johns Hopkins then turned to the invention
Dr. David R. Fischell is a serial entrepreneur who has founded nine biomedical device companies in the last fifteen years. He is chairman of the Cornell University Biomedical Engineering Advisory Board, and a Fellow of the American Institute for Medical and Biological Engineering. After earning his Ph.D. in Applied Physics from Cornell University, Dr. Fischell
NeuroPace is a privately-held company in Mountain View, CA. Their RNS® implantable stimulator, along with depth leads and cortical strip leads are designed for the treatment of medically refractory partial epilepsy. Unlike Cyberonics’ VNS IPGs, the RNS neurostimulator is designed to detect abnormal electrical activity in the brain and respond by delivering electrical stimulation to normalize brain activity